Previous Close | 2.7300 |
Open | 2.7000 |
Bid | 0.0000 x 1400 |
Ask | 0.0000 x 900 |
Day's Range | 2.6495 - 2.7282 |
52 Week Range | 0.9200 - 3.1600 |
Volume | |
Avg. Volume | 257,081 |
Market Cap | 225.655M |
Beta (5Y Monthly) | 1.41 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.0100 |
Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.55 |
Subscribe to Yahoo Finance Plus to view Fair Value for LAB
Q2 2023 Standard BioTools Inc Earnings Call
Continued operational execution improves revenue growth, margin expansion, and expense reductionSOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) (“Standard BioTools”, or the “Company”), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today reported financial results for the second quarter ended June 30, 2023. Selected Financial Results (Numbers in millions, except percentages)Quarter EndedJune 30, 2023 Qu
SOUTH SAN FRANCISCO, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced Company management will participate in the following investor conferences: Canaccord Genuity 43rd Annual Growth Conference: Michael Egholm, PhD, President and Chief Executive Officer, will participate in a fireside chat on Wednesday, August 9, 2023, at 3:30 p.m. ET.UBS MedTech, Tools and Geno